ZYBT

Peers: ZTS ELAN PAHC BGM ICCC CPHI UPC NEOG JAGX IDXX

Index	-
Market Cap	38.34M
Enterprise Value	49.79M
Income	-9.74M
Sales	16.18M
Book/sh	0.75
Cash/sh	0.25
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	269
IPO	Jan 07, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	2.37
P/B	1.71
P/C	5.16
P/FCF	22.16
EV/EBITDA	-
EV/Sales	3.08
Quick Ratio	0.80
Current Ratio	1.14
Debt/Eq	0.30
LT Debt/Eq	0.04
Option/Short	No / Yes

EPS (ttm)	-0.21
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	-25.18% -16.43%
EPS Y/Y TTM	-717.42%
Sales Y/Y TTM	-37.53%
EPS Q/Q	-2195.59%
Sales Q/Q	-40.44%
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	74.09%
Insider Trans	0.00%
Inst Own	0.34%
Inst Trans	-7.08%
ROA	-14.98%
ROE	-26.09%
ROIC	-26.28%
Gross Margin	20.41%
Oper. Margin	-60.73%
Profit Margin	-60.22%
SMA20	-9.19%
SMA50	-11.72%
SMA200	11.53%
Trades

Shs Outstand	29.73M
Shs Float	7.70M
Short Float	0.88%
Short Ratio	0.03
Short Interest	0.07M
52W High	8.01 -83.90%
52W Low	0.62 109.59%
Volatility	8.55% 17.82%
ATR (14)	0.17
RSI (14)	42.62
Beta	-2.30
Rel Volume	0.02
Avg Volume	1.97M
Volume	2,125

Perf Week	-9.15%
Perf Month	4.03%
Perf Quarter	0.78%
Perf Half Y	29.65%
Perf YTD	12.17%
Perf Year	-47.56%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	1.30
Price	1.29
Change %	-0.77%

Aug-06-26 08:00AM	Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirement (GlobeNewswire) -11.44%
Jul-21-26 10:34AM	Zhengye Biotechnology Says No Material Events Behind Unusual Trading Activity (NASDAQ:ZYBT) (InvestorsHub) -64.42%
08:30AM	Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity (GlobeNewswire)
Jun-04-26 04:05PM	Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire)
Apr-28-26 04:30PM	Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results (PR Newswire) -5.69%
09:25AM	Loading…
Apr-06-26 09:25AM	Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure (GlobeNewswire)
Feb-10-26 08:30AM	Zhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to Shareholders (GlobeNewswire)
Jul-03-25 08:30AM	Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results (PR Newswire)
May-23-25 04:05PM	Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F (GlobeNewswire) -12.33%
Jan-14-25 12:00PM	Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option (GlobeNewswire)
Jan-08-25 12:00PM	Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering (GlobeNewswire) -7.41%
Jan-06-25 05:50PM	Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering (GlobeNewswire)

Zhengye Biotechnology Holding Ltd. engages in the manufacture and sale of veterinary vaccines. It offers a range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The company was founded on March 24, 2023 and is headquartered in Jilin City, China.

Co-Chief Executive OfficerMr. Songlin Song

Chief Financial OfficerMr. Ping Wang

Chief Operating OfficerMr. Zhongyao Liu

Vice General ManagerMs. Yuhong Cheng

Co-Chief Executive OfficerMr. Aiden Han

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Zhengye Biotechnology Holding Ltd

Upgrade your Finviz experience